Case Reports:
Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report
Metrics: PDF 1552 views | HTML 1936 views | ?
Abstract
Hongqing Zhuang1,*, Xiangkun Yuan2,*, Dayong Sun3, Jianliang Bian4, Joe Y. Chang5, Zhiyong Yuan1 and Ping Wang1
1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
2 Department of Radiotherapy, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Hebei, China
3 Department of Chemo-Radiotherapy, Chengde Center Hospital, Second Clinical Medical School of Chengde Medical University, Hebei, China
4 Department of Radiotherapy, Affiliated Hospital of Hebei University, Hebei, China
5 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
* These authors have contributed equally to this work
Correspondence to:
Hongqing Zhuang, email:
Dayong Sun, email:
Jianliang Bian, email:
Keywords: bevacizumab, acquired resistance, radiation brain necrosis
Received: September 14, 2015 Accepted: January 29, 2016 Published: February 25, 2016
Abstract
The case study reported on acquired bevacizumab resistance in one patient receiving re-treatment with bevacizumab following radiation brain necrosis progression after bevacizumab was discontinued. This case offers novel and additional insight for bevacizumab treatment. Low-dose bevacizumab is effective for radiation brain necrosis, and radiation brain necrosis may progress after bevacizumab discontinuation, whereas too many cycles of bevacizumab treatment may induce drug-resistance and re-treatment failure following the progression. Therefore, more rational administration for radiation brain necrosis with bevacizumab may include three aspects: short-course treatment, timely discontinuation upon obtaining satisfactory effects (to prevent long-term medication associated resistance) and re-treatment after brain necrosis progression.
![Creative Commons License](/images/80x15.png)
PII: 7724